SEI is trading at $0.1209 consolidating above the $0.11–$0.12 support zone, where buyers are attempting to stabilize price action. RSI and MACD show easing bearishSEI is trading at $0.1209 consolidating above the $0.11–$0.12 support zone, where buyers are attempting to stabilize price action. RSI and MACD show easing bearish

Can SEI Price Extend Its Recovery Toward $0.125 in January Despite Broader Market Caution?

2026/01/04 16:00
2 min read
For feedback or concerns regarding this content, please contact us at [email protected]

After experiencing a rapid decline followed by a sharp rise, altcoins have entered the consolidation phase as traders and investors alike adjust to their new trading ranges. Early January has shown to be a crucial period in determining how quickly SEI can be stabilized and ultimately attempt to make a recovery in the short term. At press time, the coin is trading at $0.1209 with an increase of 0.64%  over the past 24 hours.

Chart Signals Hint at Stabilization

The TradingView data displays that SEI is continuing on a larger downtrend, but recently, it has begun to establish a consolidative range above the $0.11 support zone. The RSI is currently moving towards the 50 mark; this indicates a slight decrease in the amount of selling pressure that is currently affecting it.

The MACD histogram is showing the possibility of improvement, which indicates weakness in this instance of bearish pressure and could lead to an increased bullish trend. If current support can be found by the buyers, it may be possible for the price to see a minor bounce upward toward local resistance.

Source: TradingView

Also Read: SEI Price Analysis: 3 Signals Suggest a Potential Rebound

Tweet Highlights a Potential Breakout

Ali Charts, an analyst on X, publicly supported the possibility of a breakout from a descending channel in the initial time frame, with an upward target of $0.125. Holding above the breakout area would be key for this bullish model to remain valid in the immediate future.

Forecast Suggests Limited Upside

CoinCodex is forecasting that the coin will find a trade zone between $0.0847 and $0.1213 during January, with an average trading price being about $0.0963. Based on this prediction, while a move to $0.125 is a likely possibility;

However, it would likely occur at a higher level than projected by the model, and will require additional upward momentum from either the buyers or the price raw technicals to become a reality.

Source: Coincodex

In conclusion, there is potential for the coin to reach $0.125 in January, but only if the price remains above strong support and purchase volumes increase.

As long as this does not happen, SEI will stay in a careful recovery phase where the higher levels of price depend on confirmation from technical indicators as well as from market sentiment.

Also Read: SEI Could Surge to $0.95 as Falling Wedge Pattern Holds $0.11 Support

Market Opportunity
SEI Logo
SEI Price(SEI)
$0.06594
$0.06594$0.06594
-0.64%
USD
SEI (SEI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09